Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-05-23 02:33Group 1 - The Hang Seng Biotechnology ETF (159615) opened high on May 23, 2025, with an intraday increase of over 2%, and a turnover of 14.35% amounting to 48.548 million yuan, indicating active market trading [1] - The Hang Seng Biotechnology Index, which the ETF tracks, rose by 1.79%, with constituent stocks such as Kangzheng Pharmaceutical up by 8.82%, Tigermed up by 8.35%, and Ascentage Pharma-B up by 8.10% [1] - As of May 22, 2025, the Hang Seng Biotechnology ETF had a cumulative increase of 7.43% over the past week, ranking first among comparable funds, and its scale grew by 16.4037 million yuan over the past two weeks [1] Group 2 - China’s pharmaceutical giant, Hengrui Medicine, officially listed on the Hong Kong Stock Exchange, opening at a 29.4% increase to 57 HKD, with a market capitalization of 376.4 billion HKD [1] - The 2025 American Society of Clinical Oncology (ASCO) annual meeting is set to take place from May 30 to June 3 in Chicago, which is expected to be a significant catalyst for the innovative drug industry as multiple companies will disclose important clinical and R&D data [1] Group 3 - According to AVIC Securities, the innovative drug industry is expected to become a key investment theme for the year due to multiple factors, including supportive policies and improved payment conditions [2] - The Hang Seng Biotechnology Index reflects the performance of the largest 50 biotechnology companies listed in Hong Kong, with top-weighted stocks including Innovent Biologics, WuXi Biologics, and BeiGene [2] - The report suggests continued investment in innovative drugs, high-end medical devices, and medical consumption sectors, while also identifying relatively undervalued second-tier blue-chip companies [2]